文献速递肝病消化道肿瘤与早癌

他汀类药物使用与高危人群肝细胞癌风险:一项全国性巢式病例对照研究

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study.
PubMed 文献 · J Hepatol · 2017-10-26

该研究基于韩国国民健康保险服务体检队列2002—2013年数据,开展全国性巢式病例对照研究,共匹配1642例肝细胞癌(HCC)病例与8210例对照。他汀使用与HCC风险降低相关(调整OR 0.44;95%CI 0.33-0.58)。在糖尿病或肝硬化患者中该风险降低亦显著。

要点

  • 他汀使用与HCC风险降低相关(AOR 0.44;95%CI 0.33-0.58)。
  • 合并糖尿病者AOR 0.28(95%CI 0.17-0.46),无糖尿病者AOR 0.53(95%CI 0.39-0.73)。
  • 合并肝硬化者AOR 0.39(95%CI 0.26-0.60),无肝硬化者AOR 0.42(95%CI 0.32-0.57)。

核心结论

  • 他汀使用可能对HCC发生具有有益抑制作用,尤其在糖尿病或肝硬化等高危患者中。

研究设计与样本

  • 全国性巢式病例对照研究,数据来自韩国国民健康保险服务体检队列2002—2013年,共514866名参与者。
  • 1642例HCC病例按随访时间、性别和索引日期年龄匹配8210例对照。
  • 采用多变量条件logistic回归分析他汀使用与HCC的比值比(OR)及95%CI。

主要发现

  • 与未使用者相比,他汀使用与HCC发生风险降低相关(AOR 0.44;95%CI 0.33-0.58)。
  • 合并糖尿病患者他汀使用与HCC风险降低相关(AOR 0.28;95%CI 0.17-0.46),无糖尿病者为AOR 0.53(95%CI 0.39-0.73)。
  • 合并肝硬化患者他汀使用与HCC风险降低相关(AOR 0.39;95%CI 0.26-0.60),无肝硬化为AOR 0.42(95%CI 0.32-0.57)。
  • 在糖尿病患者中,无慢性并发症者他汀使用与HCC风险降低相关(AOR 0.19;95%CI 0.08-0.46),有慢性并发症者为AOR 0.34(95%CI 0.19-0.64),均与未使用者比较。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Statins are widely used to treat hypercholesterolemia. Statins may prevent hepatocellular carcinoma (HCC), but have not yet been fully studied, particularly in patients at high risk. Therefore, we investigated the risk of HCC after statin use in the whole general population and evaluated the effects of preexisting diabetes mellitus (DM) and liver cirrhosis (LC) on that risk. METHODS: A nationwide, nested case-control study was conducted with data from the National Health Insurance Service Physical Health Examination Cohort 2002-2013 in the Republic of Korea. Individuals diagnosed with HCC were matched to controls based on the time of the follow-up, sex, and age at index date. Odds ratios (ORs) and 95% confidence intervals (CIs) for HCC associated with statin use were analyzed by multivariable conditional logistic regression analyses. In total, 1,642 HCC cases were matched to 8,210 control individuals from 514,866 participants. RESULTS: Statin use was associated with reduced risk of HCC development (adjusted OR [AOR] 0.44; 95% CI 0.33-0.58) compared with nonusers. The reduction in risk was significant in the presence (AOR 0.28; 95% CI 0.17-0.46) and absence of DM (AOR 0.53; 95% CI 0.39-0.73) and in the presence (AOR 0.39; 95% CI 0.26-0.60) and absence of LC (AOR 0.42; 95% CI 0.32-0.57). Statin use also significantly reduced the risk of HCC among patients with DM, without chronic complications (AOR 0.19; 95% CI 0.08-0.46) or with chronic complications (AOR 0.34; 95% CI 0.19-0.64), compared to nonusers. CONCLUSIONS: Statin use may have a beneficial inhibitory effect on HCC development, particularly in patients with DM or LC, at high risk of HCC. LAY SUMMARY: In this longitudinal nationwide population-based nested case-control study, the association between statin use and the risk of HCC was investigated in Asian populations. Herein, we noted a beneficial effect of statin use on the development of HCC in the general population and individuals at high risk of HCC (i.e. those with diabetes or liver cirrhosis).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim G, Jang SY, Nam CM, et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J Hepatol. 2017. PMID: 29107150. doi:10.1016/j.jhep.2017.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。